The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
Open accessAbstract
BACKGROUND: Previous studies have suggested that the use of nonsteroidal antiinflammatory drugs (NSAIDs) may help to prevent Alzheimer's disease. The results, however, are inconsistent. METHODS: We studied the association between the use of NSAIDs and Alzheimer's disease and vascular dementia in a prospective, population-based cohort study of 6989 subjects 55 years of age or older who were free of dementia at base line, in 1991. To detect new cases of dementia, follow-up screening was performed in 1993 and 1994 and again in 1997 through 1999. The risk of Alzheimer's disease was estimated in relation to the use of NSAIDs as documented in pharmacy records. We defined four mutually exclusive categories of use: nonuse, short-term use (1 month or less of cumulative use), intermediate-term use (more than 1 but less than 24 months of cumulative use), and long-term use (24 months or more of cumulative use). Adjustments were made by Cox regression analysis for age, sex, education, smoking status, and the use or nonuse of salicylates, histamine Hz-receptor antagonists, antihypertensive agents, and hypoglycemic agents. RESULTS: During an average follow-up period of 6.8 years, dementia developed in 394 subjects, of whom 293 had Alzheimer's disease, 56 vascular dementia, and 45 other types of dementia. The relative risk of Alzheimer's disease was 0.95 (95 percent confidence interval, 0.70 to 1.29) in subjects with short-term use of NSAIDs, 0.83 (95 percent confidence interval, 0.62 to 1.11) in those with intermediate-term use, and 0.20 (95 percent confidence interval, 0.05 to 0.83) in those with long-term use. The risk did not vary according to age. The use of NSAIDs was not associated with a reduction in the risk of vascular dementia. CONCLUSIONS: The long-term use of NSAIDs may protect against Alzheimer's disease but not against vascular dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recognition that a robust inflammatory response contributes to AD also fuelled the discovery that long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) reduced the risk for AD, delayed disease onset, and slowed cognitive decline (McGeer et al., 1996;Stewart et al., 1997;in t' in t'Veld et al., 2001).”
From PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice (2012) · cites this paper as in t'Veld et al., 2001
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Roth, M., Tym, E., Mountjoy, C. Q., Huppert, F. A., Hendrie, H., Verma, S., & Goddard, R. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.149.6.698 · Cited by 2,090
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Determinants of disease and disability in the elderly: The Rotterdam elderly study
Albert Hofman, D., Grobbee, D. E., de Jong, P. T. V. M., & Ouweland, F. A. V. D. (1991) · European Journal of Epidemiology · doi:10.1007/bf00145007 · Cited by 1,120
Flagged first, then by citations
Research works printed but not linked: 4
- Brooks W, 1998, Neurobiol Aging, 19, S140
- Kukull WA, 1994, Neurology, 44, A237
- Cornelius C, 1998, Neurobiol Aging, 19, S28
- Time-varying explanatory variables. In: Clayton D, Hills M. Statistical models in epidemiology. Oxford, England: Oxford University Press, 1993:307-18.
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Gammanpila, U. P., Burns, A. S., Heller, R. F., & Purandare, N. B. (2007) · BMC Geriatrics · doi:10.1186/1471-2318-7-25 · Cited by 6
“Hence, we chose these over other potential preventive and treatment interventions [7-12].”
BackgroundEffects of Syzygium cumini Seed Extract on the Memory Loss of Alzheimer’s Disease Model Rats
Hossain, S., Islam, J., Bhowmick, S., Haque, M., & Rahaman, K. A. (2017) · Advances in Alzheimer s Disease · doi:10.4236/aad.2017.63005 · Cited by 7
Ioppolo, A., Eccles, M. K., Groth, D., et al. (2021) · Molecules · doi:10.3390/molecules27010176 · Cited by 7
Inflammation and neurodegeneration
Piehl, F. (2005) · Future Neurology · doi:10.2217/14796708.1.1.97 · Cited by 7
Drye, L. T., & Zandi, P. P. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000341783 · Cited by 7
Hoozemans, J. J. M. (2014) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000243 · Cited by 8
Neuroprotection in Alzheimer’s Disease
Jain, K. K. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-049-2_8 · Cited by 7
Vers une prévention de la démence ?
Alpérovitch, A., Schwarzinger, M., Dufouil, C., Dartigues, J.-F., Ritchie, K. A., & Tzourio, C. (2004) · Revue Neurologique · doi:10.1016/s0035-3787(04)70900-5 · Cited by 7
Development of antiinflammatory therapy for Alzheimer's disease
Aisen, P. S. S. (2002) · Drug Development Research · doi:10.1002/ddr.10094 · Cited by 7
Can we afford to develop treatments for dementia?
Lovestone, S. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.685 · Cited by 7
Frigerio, C. S., Kukar, T. L., Fauq, A. H., Engel, P. C., Golde, T. E., & Walsh, D. M. (2009) · Biochemistry · doi:10.1021/bi901237k · Cited by 7
Vascular factors and cognition: toward a prevention of dementia?
Tzourio, C. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306005-00004 · Cited by 7
Ibáñez-Hernández, M. G., Macías-Islas, M. Á., Zavalza-Gómez, A. B., Pacheco-Moisés, F. P., & Ortíz, G. G. (2008) · PubMed · Cited by 7
Zhu, Q., Song, Y., Qian, Y., Zhang, R., Xue, J., & Hou, Y. (2025) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2025.25 · Cited by 6
Huang, X., Huang, L., Tan, C., Wei, J.-M., Zhang, X.-H., Tan, L., & Xu, W. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13434-0 · Cited by 6
INFLAMMATION, IMMUNITY AND ALZHEIMER'S DISEASE
Combrinck, M. I., & Joska, J. A. (2008) · Cited by 6
Pharmacological Role of Heterocyclic Compounds in the Treatment of Alzheimer’s Disease: A Review
Palaniappan, S. P. (2022) · The Journal of Phytopharmacology · doi:10.31254/phyto.2022.11412 · Cited by 6
Asthana, A., Tripathi, S., & Agarwal, R. (2023) · Advances in Alzheimer s Disease · doi:10.4236/aad.2023.121001 · Cited by 6
Dileep, K. V., Remya, C., Tintu, I., & Sadasivan, C. (2013) · Frontiers in Life Science · doi:10.1080/21553769.2014.901924 · Cited by 7
Dissecting the relative influences of genes and the environment in Alzheimer's disease
Mayeux, R. P. (2004) · Annals of Neurology · doi:10.1002/ana.20037 · Cited by 6
Tang, W., He, M., Yang, B., et al. (2012) · Neurological Sciences · doi:10.1007/s10072-012-1115-9 · Cited by 6
Tratamento da doença de Alzheimer
de Assis, F., do Vale, C., Neto, Y. C., Bertolucci, P. H. F., Machado, J. C., da Silva, D. J., Allam, N., & Balthazar, M. L. F. (2011) · Dementia & Neuropsychologia · Cited by 6
Spirulina, Aging, and Neurobiology
Vila, J., Gemma, C., Bickford, P. C., Bachstetter, A. D., Strömberg, I., & Wang, Y. (2007) · CRC Press eBooks · doi:10.1201/9781420052572.ch13 · Cited by 5
Pharmacology and Clinical action of Cox-2 Selective Nsaids
Bovill, J. G. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-9192-8_18 · Cited by 6
NSAID exposure and risk of Alzheimer disease
Bennett, D. A., & Whitmer, R. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a81664 · Cited by 6
Fukami, S., Iwata, N., & Saido, T. C. (2002) · Drug Development Research · doi:10.1002/ddr.10073 · Cited by 5
Managing Alzheimer Dementia Tomorrow
Rosenthal, T. C., & Khotianov, N. (2003) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.16.5.423 · Cited by 7
Ware, W. R. (2010) · Cited by 6
Organische (und symptomatische) psychische Störungen
Hüll, M., & Förstl, H. (2012) · Elsevier eBooks · doi:10.1016/b978-3-437-22483-6.10008-7 · Cited by 6
Pasinetti, G. M., HO, L., & Pompl, P. N. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00007-6 · Cited by 6
Barbierato, M. (2012) · Padua Research Archive (University of Padova) · Cited by 6
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Romero‐Márquez, J. M., Navarro‐Hortal, M. D., Varela‐López, A., Calderón‐Iglesias, R., Puentes, J. G., Giampieri, F., Battino, M. A., Sánchez‐González, C., Xiao, J., García‐Ruiz, R., et al. (2025) · Food Frontiers · doi:10.1002/fft2.70013 · Cited by 6
Matuszewska, M., Wilkaniec, A., Gąssowska-Dobrowolska, M., Cieślik, M., Olech-Kochańczyk, G., Pałasz, E., Gawinek, E., Strawski, M., & Czapski, G. A. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1619583 · Cited by 6
Novel Indomethacin Action: Selective and Direct Activation of Protein Kinase C-e
Kanno, T., Tsuchiya, A., Shimizu, T., et al. (2012) · Cellular Physiology and Biochemistry · doi:10.1159/000341456 · Cited by 5
Inflammatory Processes Exacerbate Degenerative Neurological Disorders
McGeer, P. L., McGeer, E. G., & Schwab, C. (2009) · Springer eBooks · doi:10.1007/978-0-387-87995-6_10 · Cited by 6
Therapeutic Strategies in Neurodegenerative Diseases
Anderson, K. M., & Mosley, R. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_42 · Cited by 5
The Role of Inflammation in Alzheimer’s Disease
Müller, N., Krause, D., Schwarz, M., Weidinger, E., & Reinisch, V. M. (2015) · Current topics in neurotoxicity · doi:10.1007/978-3-319-13602-8_15 · Cited by 5
Znaczenie cyklooksygenaz w neurotoksyczności peptydów amyloidu β w chorobie Alzheimera
Cąkała, M., & Strosznajder, J. B. (2010) · Neurologia i Neurochirurgia Polska · doi:10.1016/s0028-3843(14)60407-2 · Cited by 5
Prevention of Alzheimer's Disease and Other Dementias
Woodward, M. C. (2003) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr2003332138 · Cited by 5
Sankowski, R., Herring, A., Keyvani, K., Frenzel, K., Wu, J., Röskam, S., Noelker, C., Bacher, M., & Al‐Abed, Y. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00163 · Cited by 5
Morin-Alain, V., Larouche, E., Chouinard, A.-M., Audet, M.-C., Goulet, S., Rousseau, L.-S., & Hudon, C. (2020) · OBM Integrative and Complementary Medicine · doi:10.21926/obm.icm.2002022 · Cited by 3
Association between aspirin use and risk of dementia: a systematic review and meta-analysis
Tao, T., Feng, G., & Fang, Y. (2023) · European Geriatric Medicine · doi:10.1007/s41999-023-00877-9 · Cited by 5
Eden, B. D., Rice, A. J., Lovett, T. D., Toner, O. M., Geissler, E. P., Bowman, W. E., & Young, S. C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.016 · Cited by 5
Mhatre, M., & Hensley, K. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50155-1 · Cited by 4
Lack of enantiomeric influence on the brain cytoprotective effect of ibuprofen and flurbiprofen
López-Villodres, J. A., Cruz, J. P. D. L., Muñoz-Marín, J., Guerrero, A., Reyes, J. J., & Correa, J. A. G. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0661-7 · Cited by 5
Kawahara, M. (2003) · Eisei kagaku · doi:10.1248/jhs.49.341 · Cited by 5
Folkesson, R., Winblad, B. G., & Benedikz, E. (2002) · Current Opinion in Psychiatry · doi:10.1097/00001504-200207000-00015 · Cited by 5
Neurodegenerative diseases and memory
Wenk, G. L. (2007) · Elsevier eBooks · doi:10.1016/b978-012372540-0/50017-0 · Cited by 5
Neuroinflammation in Preclinical Alzheimer's Disease: A Review of Current Evidence
Watermeyer, T., Raymont, V., & Ritchie, K. A. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000434 · Cited by 5
Regulation of glial cyclooxygenase by bradykinin
Levy, E., & Fleisher‐Berkovich, S. (2007) · Peptides · doi:10.1016/j.peptides.2007.01.013 · Cited by 5
Amyloid Hypothesis and Alzheimer's Disease
Sun, X., & Zhang, Y. (2011) · InTech eBooks · doi:10.5772/28947 · Cited by 4
Shie, F., & Ling, Z. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.4.419 · Cited by 4
Murraya koenigii Leaves and Their Use in Dementia
Mani, V., Ahmad, A., Ramasamy, K., Lim, S. M., & Majeed, A. B. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407824-6.00097-5 · Cited by 4
Prospects for Antioxidant Therapy in Mild Cognitive Impairment and Alzheimer's Disease
Nunomura, A., Perry, G. L., & Smith, M. A. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50161-7 · Cited by 4
DeKosky, S. T., & López, O. L. (2007) · Blue books of neurology · doi:10.1016/s1877-184x(09)70053-x · Cited by 5
Inhibitory effect of somatostatin on prostaglandin E2 synthesis by primary neonatal rat glial cells
Dror, N., Tveria, L., Meniv, I., Ben-Shmuel, S., Filipovich‐Rimon, T., & Fleisher‐Berkovich, S. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.06.005 · Cited by 4
Similar Enzymes, Different Mechanisms
DeKosky, S. T. (2003) · Archives of Neurology · doi:10.1001/archneur.60.4.632 · Cited by 4
Evaluation of Factors of Importance for Clinical Dementia Diagnosis
Nägga, K., Garcia, J., Zetterberg, H., Blennow, K., Gottfries, J., & Marcusson, J. O. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000084554 · Cited by 4
Nonsteroidal antiinflammatory drugs as therapeutic agents for Alzheimer's disease
Golde, T. E., Eriksen, J. L., Weggen, S., Sagi, S. A., & Koo, E. H. (2002) · Drug Development Research · doi:10.1002/ddr.10093 · Cited by 4
“Indeed, the current data suggesting that oral salicylates do not confer protection from AD argues that COX-independent action of NSAIDs contribute to their protective properties in AD [in t’ Veld et al., 2001].”
BackgroundRheumatoid Arthritis and Alzheimer Disease: Possible Cellular and Molecular Links
Ferraccioli, G., & Gremese, E. (2012) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.1000104 · Cited by 4
“[17] prospectively analysed almost 7000 healthy subjects older then 55 years using NSAIDs (approximately 83% using diclofenac, ibuprofen and naproxen) for joint symptoms (about 3.”
BackgroundImplications of transcriptional coactivator CREB binding protein complexes in rheumatoid arthritis
Nakajima, T., Aratani, S., Nakazawa, M., Hirose, T., Fujita, H., & Nishioka, K. (2004) · Modern Rheumatology · doi:10.1007/s10165-003-0258-1 · Cited by 4
Dementia: Can it be prevented?
Woodward, M. C., Brodaty, H., Budge, M. M., Byrne, G. J., Flicker, L. A., Hecker, J. R., & Srikanth, V. K. (2005) · Cited by 3
Talking the talk but not walking the walk: barriers to person centred care in dementia
Hill, H. (2023) · Figshare · doi:10.26181/21844080 · Cited by 4
Khalifa, S. F., El-Taweel, F. M., Salama, M., & el-Magd, M. (2023) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2023.2252635 · Cited by 3
Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of Alzheimer´s Disease
Radermacher, J., Erhardt, V. K. J., Walzer, O., Haas, E. C., Kuppler, K. N., Zügner, J. S. R., Lauer, A. A., Hartmann, T., Grimm, H. S., & Grimm, M. O. W. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117969 · Cited by 3
Is there room for Darwinian medicine and the hygiene hypothesis in Alzheimer pathogenesis?
Griffin, W. S. T., & Mrak, R. E. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8903-1_14 · Cited by 2
Alzheimer's Disease: Clinical Trials and Future Perspectives
Lee, K. S., & Suh, H. S. (2012) · 대한정신약물학회지 · Cited by 2
Camins, A., Ettcheto, M., & Busquets, O. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.257513 · Cited by 3
Patil, S. P., DiFlumeri, J., Wellington, J., Fattakhova, E., & Oravic, M. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2022.110865 · Cited by 3
Progress in the development of new drugs in Alzheimer’s disease
Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B. J. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0103-0 · Cited by 3
Aspirin and anti-inflammatory drugs for the prevention of dementia
Jordan, F., McGuinness, B., Murphy, K., Passmore, P., Kelly, J. P., & Devane, D. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011459 · Cited by 3
Key Transcription Factors Linking Macular Degeneration and Alzheimer’s Disease
Eichenbaum, J. W. (2019) · World Journal of Ophthalmology & Vision Research · doi:10.33552/wjovr.2019.01.000516 · Cited by 3
Wang, Z., Gao, R., Huang, Y., et al. (2009) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-009-0323-x · Cited by 3
“Furthermore, several neurodegenerative disorders, including Alzheimer, polyglutamine, and Parkinson diseases, are thought to be caused by an accumulation of protein aggregates in the brain [12] , and HSPs such as Hsp70 and Hsp40 are shown to suppress the toxicity of these diseases [13] . Recently, long-term use of non…”
BackgroundDietary Fatty Acids and Cognitive Function
Kalmijn, S. (2002) · Springer eBooks · doi:10.1007/978-1-4615-1067-3_3 · Cited by 3
Cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory drugs in the management of arthritis
Kraus, V. B. (2003) · Foot and Ankle Clinics · doi:10.1016/s1083-7515(03)00035-4 · Cited by 3
Is there a role fordiet in cognitive rehabilitation?
Parrott, M. D., & Greenwood, C. E. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9781316529898.020 · Cited by 3
Parayath, N. N., Pawar, G. N., Avachat, C., Miyake, M. M., Bleier, B. S., & Amiji, M. M. (2017) · Routledge eBooks · doi:10.1201/9781315152356-15 · Cited by 3
Schwabe, U. (2006) · Springer eBooks · doi:10.1007/3-540-30505-x_11 · Cited by 3
Weggen, S., Czirr, E., Leuchtenberger, S., & Eriksen, J. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_11 · Cited by 3
The phenylic hydroxyl group is essential for the induction of stress response by sodium salicylate
Yamagishi, N., Tokunaga, S., Ishihara, K., Saito, Y., & Hatayama, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.008 · Cited by 3
Dementie: ziekte of veroudering?
Jonger, C. (2002) · Neuropraxis · doi:10.1007/bf03071032 · Cited by 3
“Ook in de Rotterdam-studie werd aangetoond dat de kans op dementie afneemt bij gebruik van ontstekingsremmers in het preklinisch stadium (In ’t Veld et al., 2001).”
BackgroundMcGoldrick, K. E. (2004) · Survey of Anesthesiology · doi:10.1097/01.sa.0000132028.95631.1d · Cited by 3
Inflammation-associated risk factors for Alzheimer s disease and dementia
Eriksson, U. K. (2010) · Figshare · Cited by 3
Alzheimer's Disease and Mild Cognitive Impairment
Jones, D. T., Bruns, M. B., & Petersen, R. C. (2018) · Wiley eBooks · doi:10.1002/9781118772034.ch21 · Cited by 3
A novel GSK3β inhibitor ameliorates tau aggregation and neuroinflammation in Alzheimer's disease
Ning, X., Liu, W., Zhou, L., Wang, N., Li, X., Wu, L., Li, Z., Yang, A.-Z., Liu, S., Xu, Z., et al. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106090 · Cited by 2
Cheng, Y.-C., Lu, C.-L., Wang, J., Tsai, M. L., & Lu, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1760959 · Cited by 2
Keynejad, R. C., Holt, C., & Rao, T. (2015) · BJPsych Bulletin · doi:10.1192/pb.39.6.315 · Cited by 2
Clinical effects of the NChinpi on the cognitive impairment of patients with Alzheimer’s disease
Seki, T. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.145.234 · Cited by 2
Geamănu, A., Baciu, A. E., Pîrvulescu, R. A., Iancu, R. C., Anton, N., Popa‐Cherecheanu, A., Ghiță, M., & Romanitan, M. O. (2024) · Medicina · doi:10.3390/medicina60060846 · Cited by 2
Czapski, G. A., Matuszewska, M., Cieślik, M., & Strosznajder, J. B. (2024) · Folia Neuropathologica · doi:10.5114/fn.2024.138140 · Cited by 2
Infection, Neuroinflammation and Interventions for Healthy Brain and Longevity
Fülöp, T., Ramassamy, C., Lacombe, G., Frost, E. H., Cohen, A. A., Rodrigues, S., Desroches, M., Hirokawa, K., Laurent, B., & Witkowski, J. M. (2024) · Healthy ageing and longevity · doi:10.1007/978-3-031-68513-2_12 · Cited by 2
Roles of Innate Immunity and Inflammation in the Aging Brain
Okun, E., Chen, X., Bašta, M., & Mattson, M. P. (2011) · Oxidative stress and disease · doi:10.1201/b11014-2 · Cited by 2
Treatment of Alzheimer's disease
Sano, M. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.033 · Cited by 2
Andreasson, K. I., & Montine, T. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-73894-9_6 · Cited by 3
Understanding and Treating Alzheimer’s Disease
Kumar, U., Roland, A., & Burbidge, S. A. (2007) · Springer eBooks · doi:10.1007/1-4020-5058-5_4 · Cited by 2
Modulation of Adult Neurogenesis by the Nitric Oxide System
Bruno, P., Ana, I., Caetana, M., & Ins, M. (2013) · InTech eBooks · doi:10.5772/54982 · Cited by 2
Primary prevention of dementia
Jones, R. W. (2007) · Psychiatry · doi:10.1016/j.mppsy.2007.10.002 · Cited by 2
Prettyman, R. J. (2007) · BMJ · doi:10.1136/bmj.39220.421262.3a · Cited by 2
In vitro effect of PPAR-γ2 Pro12Ala polymorphism on the deposition of Alzheimer's amyloid-β peptides
d’Abramo, C., Zingg, J.-M. A., Pizzuti, A., Argellati, F., Pronzato, M. A., & Ricciarelli, R. (2007) · Brain Research · doi:10.1016/j.brainres.2007.07.065 · Cited by 2
Metadata
- Authors
- in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C.
- Affiliations
- Erasmus MC (NL)
- National Institutes of Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-11-22
- Volume
- 345
- Issue
- 21
- Pages
- 1515-1521
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2083556882
- Semantic Scholar
- 29c01ac52ec50618ec7b3b87ca55b707ca397434
- Cited by
- 1,196
- References
- 44
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 18 · 2023: 23 · 2022: 26 · 2021: 33 · 2020: 23 · 2019: 40 · 2018: 38 · 2017: 28 · 2016: 40 · 2015: 49 · 2014: 49 · 2013: 39 · 2012: 50
- FWCI
- 52.61
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- nonsteroidal anti-inflammatory drugs, Alzheimer's disease, vascular dementia, dementia risk, long-term NSAID use, older adults
- MeSH terms
- Aged, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prospective Studies, Risk, Salicylates, Dementia, Vascular, Cohort Studies, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
